Category: Delcath Systems Inc.
Amid a flurry of layoffs and restructuring after failed attempts to win FDA approval, New York device maker Delcath Systems aims for a $7.5 million funding round.
New York's Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purposes."
Troubled medical device maker Delcath cuts 33% of its workforce in hopes of saving some cash.
Medical device company Delcath (NSDQ:DCTH) fired 33% of its workforce, amounting to 21 employees , as the company looks for avenues to save some cash and "increase operating efficiencies".
Targeted chemotherapy systems maker Delcath implements a "leadership transition plan,' ousting president & CEO Eamonn Hobbs amid tumbling share prices and lost affections as the FDA issues its final non-approvable notice.
The FDA's final decision not to approve Delcath's liver cancer treatment sends share prices down some 8%.
Shares of Delcath (NSDQ:DCTH) dropped again yesterday on news of the FDA's final decision regarding its Melblez Kit liver cancer treatment.
Delcath Systems announces that it will lay off about 20% of its U.S. employees and redouble its efforts in Europe.
Queensbury, N.Y.-based Delcath (NSDQ:DCTH) announced last week that it plans to pare its workforce by about 20%, the latest in a series of layoff announcements from the oncology devices maker. This is the 3rd time this year that Delcath has announced imminent layoffs, having announced smaller cuts in April and larger layoffs in January.
Edwards Lifesciences said its CFO, Thomas Abate, plans to retire once a replacement is found later this year.
Edwards Lifesciences (NYSE:EW) said its finance chief, Thomas Abate, plans to retire later this year after a replacement is found.
The Irvine, Calif.-based medical device company said Abate, 60, will stay on as CFO while the search goes on. Edwards hired Peter Crist of Crist/Kolder Associates to assist in the quest, according to a press release.
An FDA advisory panel unanimously recommends against approval for Delcath's liver cancer treatment, citing a too-high mortality rate, slashing nearly half the value from the company's stock.
Shares of Delcath (NSDQ:DCTH) have lost nearly half their value so far today after an FDA panel recommended against approval for its liver cancer treatment.